Chipscreen Biosciences Ltd.

Many of China’s homegrown first-in-class drugs have had a hard time becoming rainmakers for their originators, with few becoming blockbusters in domestic or international sales terms. Since the first

Bayer’s best hope of reclaiming its past dominance in China’s oral diabetes drug market has collapsed. The German major’s setback in the space, packed with low-priced competitors, came as local partne

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Daiichi Sankyo Pays ¥9.5bn F

In June, Tasly Pharmaceutical Co. Ltd. made an official filing for an initial public offering in Hong Kong, the plan being to list Tasly Biologics, a subsidiary of the major Chinese traditional medi